Using engineered cells to treat Alzheimer's disease
Regulated gene circuits for Alzheimer's disease therapy
This study is exploring new ways to treat Alzheimer's disease by using specially modified brain cells that can adapt to the changes caused by the disease, with the hope of better protecting the brain and slowing down its decline.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10871284 on NIH RePORTER |
What this research studies
This research investigates innovative approaches to treat Alzheimer's disease by utilizing genetically engineered astrocytes and microglia. These cells are designed to respond dynamically to the disease's progression, potentially enhancing neuroprotection and combating neurodegeneration. The project aims to develop methods that allow these cells to coordinate their protective behaviors based on the specific pathological signatures present in the brain. By focusing on cell-based therapies, the research seeks to address the limitations of current treatments that primarily target neurotransmitter imbalances.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those showing early signs of cognitive decline associated with the condition.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly slow down or even reverse the progression of Alzheimer's disease.
How similar studies have performed: While there have been various attempts to use cell-based therapies for neurodegenerative diseases, this specific approach using engineered astrocytes and microglia is relatively novel and has not been extensively tested.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Brunger, Jonathan Matthew — Vanderbilt University
- Study coordinator: Brunger, Jonathan Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.